Department of Laboratory Medicine, Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm SE-141 86, Sweden; Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm SE-106 91, Sweden.
Department of Laboratory Medicine, Division of Clinical Immunology and Transfusion Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm SE-141 86, Sweden.
Curr Opin Biotechnol. 2021 Aug;70:75-82. doi: 10.1016/j.copbio.2020.12.015. Epub 2021 Jan 11.
Typical traditional probiotics lactobacilli and bifidobacteria are gaining great interest to be developed as living diagnostics and therapeutics for improving human health. However, the mechanistic basis underlying their inherent health beneficial property remain incompletely understood which can slow down the translational pipeline in the functional food and pharmaceutical field. Efficient genome editing will advance the understanding of the molecular mechanism of the probiotics' physiological properties and their interaction with the host and the host microbiota, thereby further promote the development of next-generation designer probiotics with improved robustness and tailored functionalities. With the expansion of genome editing strategies such as CRISPR-Cas-based tools and IPSD assisted genome engineering as well as other synthetic biology technologies, the research and application of these health-promoting bacteria for the food and pharmaceutical industry will be further enhanced.
典型的传统益生菌乳杆菌和双歧杆菌作为改善人类健康的活体诊断和治疗方法越来越受到关注。然而，其内在健康有益特性的机制基础仍不完全清楚，这可能会减缓功能性食品和制药领域的转化进程。高效的基因组编辑将促进对益生菌生理特性及其与宿主和宿主微生物组相互作用的分子机制的理解，从而进一步推动具有增强的稳定性和定制功能的下一代设计益生菌的发展。随着基因组编辑策略（如基于 CRISPR-Cas 的工具和 IPSD 辅助基因组工程以及其他合成生物学技术）的扩展，这些促进健康的细菌在食品和制药行业的研究和应用将得到进一步加强。
